[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"perioperative\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:perioperative":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,54,66,94,120,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100054043","intraoperative-cognitive-load-in-anesthesia-nurses-across-anesthetic-phases-100054043",false,"NCT07568158","Intraoperative Cognitive Load in Anesthesia Nurses Across Anesthetic Phases","Carga Cognitiva Intraoperatoria Del Enfermero\u002Fa de Anestesia Según la Fase Del Acto Anestésico: Estudio Observacional Con NASA-TLX","ENCOPER","Inclusion Criteria:\n\n* Registered nurse anesthetist actively working at Hospital Clínic de Barcelona.\n* Minimum 3 months in the current anesthesia nursing position.\n* Voluntary participation with signed informed consent.\n* Scheduled surgery (including deferred urgent surgery) or solid organ transplantation.\n* General anesthesia (endotracheal intubation or laryngeal mask airway) or spinal anesthesia with sedation.\n* Minimum duration of 30 minutes.\n\nExclusion Criteria:\n\n* Refusal to participate or withdrawal of informed consent.\n* Spinal anesthesia without sedation.\n* Exclusive regional anesthesia without sedation.\n* Sedation alone without regional technique.\n* Duration less than 30 minutes.\n* Cases involving an unexpected intraoperative emergency requiring urgent additional personnel.\n* Cases started under spinal anesthesia converted to general anesthesia for any clinical or technical reason.",true,"ALL","18 Years",{"count":21,"type":22},50,"ESTIMATED","8 Months","OBSERVATIONAL","The goal of this observational study is to measure the cognitive load (mental effort) of anesthesia nurses during real surgical procedures at Hospital Clínic de Barcelona, Spain. The main questions it aims to answer are:\n\n* Does cognitive load vary across the three phases of anesthetic care (induction, maintenance, and emergence\u002Frecovery)?\n* Is cognitive load higher during general anesthesia than during spinal anesthesia with sedation?\n* How do surgical specialty and patient complexity relate to cognitive load?\n* How does monitor alarm perception relate to cognitive load during surgery?\n\nParticipants (anesthesia nurses) will complete the NASA Task Load Index (NASA-TLX) questionnaire - a validated 6-item tool measuring mental effort - three times per surgical case: after induction or spinal block, during maintenance, and after patient awakening or sedation reversal. They will also answer 4 brief questions about alarm management at the end of each case. No changes are made to clinical care. Participation adds approximately 11 minutes per surgical case.",[27,28,29,30,31,32],"Alarm Fatigue","Perioperative","Patient Safety","Cognitive Load","Performance","Cognitive Load, Performance",[34,35,36,37,38,29,39,40],"NASA-TLX","Anesthesia Nursing","Perioperative Nursing","Mental Workload","Intraoperative","Monitor Alarms","Operating Room","RECRUITING","2026-07-10",{"date":44,"type":45},"2026-07-13","ACTUAL",{"date":47,"type":45},"2026-06-01",{"date":49,"type":22},"2027-02-28",{"name":51,"class":52},"Hospital Clinic of Barcelona","OTHER",1,{"id":55,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":56,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":57,"keywords":58,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":63,"leadSponsor":65,"locationsCount":53},"100636628",{"count":21,"type":22},[27,28,29,30,31,32],[34,35,36,37,38,29,39,40],"2026-06-15",{"date":61,"type":45},"2026-06-17",{"date":47,"type":45},{"date":64,"type":22},"2027-01-01",{"name":51,"class":52},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":53},"100517070","the-effect-of-combined-iron-protocols-on-perioperative-allogeneic-transfusion-100517070","NCT06012760","The Effect of Combined Iron Protocols on Perioperative Allogeneic Transfusion","Effect of Iron Sucrose Combined With Human Erythropoietin and Vitamin C on Perioperative Allogeneic Red Blood Cell Infusion in Major Cardiac Surgery","CIPAT","Inclusion Criteria:\n\n1. Participants must be at least 18 years of age.\n2. Major cardiac surgery should encompass procedures such as coronary artery bypass grafting (CABG), valve surgery, or a combination of both.\n3. Iron deficiency anemia is defined as having a ferritin level below 100 μg\u002FL or a ferritin level below 300 μg\u002FL accompanied by a transferrin saturation below 25%. Additionally, hemoglobin levels should range between 90 and 130 g\u002FL for men or between 90 and 120 g\u002FL for women.\n4. The American Society of Anesthesiologists (ASA) classification should fall within Grade 1-3.\n5. Prior to participation, the patient or their legal representative must provide informed consent.\n\nExclusion Criteria:\n\n1. Contraindications for the administration of iron sucrose, ascorbic acid, or rHuEPO.\n2. Presence of a temperature exceeding 37.5 °C or the utilization of non-prophylactic antibiotics.\n3. Individuals with a weight equal to or less than 50kg.\n4. Individuals with a family history of haemochromatosis or thalassaemia, or those with a transferrin saturation level exceeding 50% or a documented history of iron overload.\n5. Presence of other known haematological disorders such as folic acid or vitamin B12 deficiency, haemolytic anaemia, haemoglobinopathies, iron granulocytic anaemia, G6PD deficiency, etc.\n6. Requirement for emergency surgical intervention.\n7. Severe hepatic or renal impairment, ALT \\>3 times the upper limit of normal value or AST \\>3 times the upper limit of normal value, creatinine \\>1.5 times the upper limit of normal value\n8. Pregnant or lactating women\n9. history of blood transfusion, intravenous iron or ascorbic acid use within 12 weeks prior to surgery\n10. Acute blood loss, gastrointestinal bleeding, etc. in the preoperative period.",{"count":75,"type":22},400,"INTERVENTIONAL",[78],"NA","The goal of this clinical trial is to learn if a combined iron supplementation regimen can reduce the need for blood transfusions in adults with iron-deficiency anemia undergoing major elective cardiac surgery. The trial will also look at whether this regimen is safe and well tolerated. The main questions it aims to answer are:\n\nDoes the combined regimen lower the amount of allogeneic red blood cell transfusion needed during and after surgery?\n\nAre there any side effects or safety concerns associated with the regimen?\n\nResearchers will compare the combined iron supplementation (sucrose iron, erythropoietin, and vitamin C) to standard care to see if it helps reduce blood transfusions.\n\nParticipants will:\n\nReceive either the combined regimen or standard care before surgery\n\nUndergo major elective cardiac surgery under general anesthesia\n\nBe monitored for blood transfusion needs and recovery up to 90 days after surgery",[81,82,28,83,84],"Anemia","Iron Deficiency Anemia","Transfusion","Cardiac Surgery","2026-05-29",{"date":87,"type":45},"2026-06-02",{"date":89,"type":45},"2025-01-04",{"date":91,"type":22},"2028-03-31",{"name":93,"class":52},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":53},"100615491","the-pneumorator-study-100615491","NCT07293299","The PneumoRator Study","Clinical Validation of the PneumoRator Respiratory Rate Sensor in a Perioperative Cohort","Inclusion Criteria:\n\n1. Have undergone or are referred for CPET\n2. are scheduled for elective surgery and expected to have \\>24 hours postoperative hospital stay\n3. Will be admitted to the Surgical High Dependancy Unit (SHDU) as part of their planned care\n4. will receive invasive arterial pressure monitoring as part of routine care\n5. are aged 18 or over\n6. have the capacity to give consent to participate\n\nExclusion Criteria:\n\n1. do not proceed to surgery following CPET referral\n2. are aged less than 18 years\n3. do not have capacity to consent\n4. decline to consent\n5. have sensitivity or allergy to medical adhesives\n6. patients with fragile, erythematous, or broken skin at the site of PnemoRator attachment or any other condition which, in the view of the clinical research team, may mean that the use of the PnemoRator device and adhesive is likely to cause patient harm.\n7. patients with implantable electronic medical devices (e.g. pacemakers, nerve stimulators)",{"count":21,"type":22},"Healthcare workers measure heart rate, blood pressure, temperature, oxygen levels and breathing rate to monitor how unwell a patient is. All these apart from breathing rate are now normally measured by machines. But there still isn't a machine that does this well enough for breathing rate to be used in most places. The machines that do exist are either uncomfortable or don't work well on patients who are moving. Instead, a healthcare worker will count the number of breaths a patient takes. This needs staff time and isn't very accurate.\n\nIt is known that changes in breathing rate can happen any time. But healthcare systems normally only measure it every few hours because it takes time. Breathing rate could be monitored all the time, we might pick up people getting sick earlier and be able to treat them more quickly, which could save lives.\n\nA team at the University of Southampton has made a small device, called a PneumoRator, that gets stuck to onto a person's chest. Once stuck there it can measure their breathing rate and store or send that information wirelessly. The device has been tested on healthy volunteers but has never been tested on patients in hospital.\n\nIn this study the team will put the device on patients having major operations. The investigators will record information already collected about patients during normal care. This includes their breathing rate using the best measurement we have, where a patient's breathing is measured by a gas they breathe out. The gas is carbon dioxide, and the measurement is called capnography. This way of measuring is only used in operating theatres and intensive care units but is a good way to check if the PneumoRator is accurate.\n\nThe investigators want to attach the PneumoRator to patient's chests before they go to sleep for their operation and leave it there for the first few days after their operation. This will let them see how the PneumoRator compares to capnography and manual breath counting. It will also let them see how the device works at different times in the patient's journey. The investigators will look at the time when patients are asleep, when breathing is controlled by a machine. Then when patients wake up investigators can measure with both capnography and the PneumoRator. Finally, when patients go to the high dependency ward, investigators will compare it against manual counting. The study team will also ask patients how they found wearing the device and any problems they found.\n\nWith this information the investigators hope to show the PenumoRator is accurate at measuring breathing rate and comfortable for patients. This will help them get the device approved for use in hospitals and other places where breathing rate needs to be measured accurately.",[104,105,28],"Respiratory","Monitored Anaesthesia Care",[107,108,109,110],"monitoring","respiratory rate","sensor","wearable","2025-12-16",{"date":113,"type":45},"2025-12-19",{"date":115,"type":45},"2025-04-25",{"date":117,"type":22},"2026-04-24",{"name":119,"class":52},"University Hospital Southampton NHS Foundation Trust",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":76,"phases":130,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":4},"100611533","phase-2-ivonescimab-monotherapy-or-in-combination-with-chemotherapy-as-neoadjuvantadjuvant-therapy-for-resectable-non-small-cell-lung-cancer-100611533","NCT07241819","Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant\u002FAdjuvant Therapy for Resectable Non-small Cell Lung Cancer","Evaluate the Efficacy and Safety of Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant\u002FAdjuvant Therapy for Resectable Non-small Cell Lung Cancer","Inclusion Criteria:\n\n1. Voluntarily sign a written informed consent form;\n2. Aged ≥ 18 years and ≤ 75 years , both males and females are eligible;\n3. ECOG PS score of 0 or 1;\n4. Patients with non-small cell lung cancer confirmed by histopathology or cytology, and with resectable clinical stage II-IIIB (T3N2) (according to the 8th edition of lung cancer TNM staging by the Union for International Cancer Control and the American Joint Committee on Cancer);\n5. No prior anti-tumor treatment has been received;\n6. No known EGFR sensitive mutations\u002FALK gene translocations;\n\nExclusion Criteria:\n\n1. Patients with large cell carcinoma, mixed-cell lung cancer, or those with small cell lung cancer components in the mixture;\n2. Presence of locally advanced unresectable or metastatic disease;\n3. Palliative local treatment for non-target lesions within 2 weeks before the first administration; receipt of non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, tumor necrosis factor, etc., excluding IL-11 used for the treatment of thrombocytopenia) within 2 weeks before the first administration; receipt of Chinese herbal medicines or proprietary Chinese medicines with anti-tumor indications within 1 week before the first administration.\n4. Severe infection occurred within 4 weeks before the first administration, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia; active infection treated with systemic anti-infective therapy within 2 weeks before the first administration (excluding antiviral therapy for hepatitis B or hepatitis C);\n5. Major surgical operation or severe trauma occurred within 4 weeks before the first administration, or those with a plan for major surgical operation within 4 weeks after the first administration (determined by the researcher); minor local surgery performed within 3 days before the first administration (excluding peripherally inserted central catheterization and venous access port implantation);\n6. History of severe bleeding tendency or coagulation dysfunction; presence of clinically significant bleeding symptoms within 1 month before the first administration, including but not limited to gastrointestinal bleeding, hemoptysis (defined as coughing up or expectorating ≥ 1 teaspoon of fresh blood or small blood clots, or coughing up only blood without sputum; those with blood-tinged sputum are allowed to enroll), nasal bleeding (excluding epistaxis and retrograde epistaxis); receipt of continuous antiplatelet or anticoagulant therapy within 10 days before the first administration.","75 Years",{"count":129,"type":22},66,[131],"PHASE2","This study is a prospective, II Phase clinical trial designed to evaluate the efficacy and safety of ivonescimab as monotherapy or in combination with platinum-based chemotherapy in the perioperative treatment of resectable non-small cell lung cancer (NSCLC).\n\nPatients are stratified by PD-L1 expression level (TPS ≥50% vs. \\\u003C50%) and randomized in a 2:1 ratio to differentiated neoadjuvant treatment arms: PD-L1≥50% subgroup: Ivonescimab monotherapy (4 cycles) vs. ivonescimab + platinum-based chemotherapy (4 cycles); PD-L1\\\u003C50% subgroup: Ivonescimab + 1 cycle of chemotherapy followed by 3 cycles of monotherapy vs. ivonescimab + platinum-based chemotherapy (4 cycles). All patients subsequently receive 13 cycles of ivonescimab as adjuvant maintenance therapy postoperatively.\n\nAs the first study to explore a PD-L1-directed chemotherapy de-escalation strategy, this trial aims to reduce treatment toxicity while maintaining efficacy, thereby providing a novel personalized precision therapy pathway for resectable NSCLC.",[134,28],"II-IIIB (T3N2) Resectable Non-small Cell Lung Cancer","NOT_YET_RECRUITING","2025-11-18",{"date":138,"type":45},"2025-11-21",{"date":140,"type":22},"2025-11-30",{"date":142,"type":22},"2028-11-30",{"name":144,"class":52},"Peking University Cancer Hospital & Institute",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":17,"sex":18,"minAge":152,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":156,"conditions":157,"keywords":160,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":5},"100409244","pediatric-perioperative-satisfaction-questionnaire-100409244","NCT04608968","Pediatric Perioperative Satisfaction Questionnaire","Development and Validation of a Perioperative Satisfaction Questionnaire in Children Population","Inclusion criteria:\n\n* children 7 years and older\n* elective surgery\n* general anesthesia\n* abiliy to understand and read questions\n\nExclusion criteria:\n\n* emergency\n* cognitive trouble\n* intellectual disability","7 Years","17 Years",{"count":155,"type":22},600,"The aim of this study is to develop and validate a self-report questionnaire to evalutate the satisfaction of the children after surgery.",[28,158,159],"Children","Satisfaction",[161,162,158,163,164],"Validity","Questionnaire","health quality of life","Self report","2024-11-25",{"date":167,"type":45},"2024-11-27",{"date":169,"type":45},"2020-09-01",{"date":171,"type":22},"2026-12-01",{"name":173,"class":52},"University Hospital, Montpellier"]